Literature DB >> 9758238

Emerging management strategies for obesity.

P G Kopelman1.   

Abstract

Management strategies for obesity, which include drug therapy, are emerging as a consequence of the increasing recognition of the medical seriousness of obesity. Obesity requires appropriate and effective management by suitably trained members of a multidisciplinary team, with treatment programmes putting equal importance on weight reduction and its maintenance. Such programmes must also take into account the reduction in risk from co-morbid conditions after modest weight loss (5-10% of initial body weight). The use of an anti-obesity drug may be justified for patients at risk from obesity where dietary methods, including exercise and behaviour modification, have failed to achieve a 10% reduction in initial body weight after at least three months from the start of the episode of managed care. Anti-obesity drugs must be prescribed in an appropriate setting, with patients being reviewed on a regular basis. Essential elements for managed weight loss include, a printed management programme, appropriate equipment, specified and realistic weight-loss goals, documentation of individual patient's health risks, and clearly defined follow-up procedures with explicit guidelines for the use of drugs and notification of other doctors involved in the patient's care. The process of drug treatment necessitates a system of regular medical audit. Many health-care professionals and lay persons remain sceptical about the scientific value of anti-obesity drugs. The emergence of increasingly specific and effective agents underlines the importance of ensuring appropriate use for patients at risk from obesity.

Entities:  

Mesh:

Year:  1998        PMID: 9758238

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  1 in total

1.  Ischemic colitis after mesotherapy combined with anti-obesity medications.

Authors:  Jong Bin Kim; Won Moon; Seun Ja Park; Moo In Park; Kyu-Jong Kim; Jae Nam Lee; Seong Joo Kang; Lee La Jang; Hee Kyung Chang
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.